The U.S. Food and Drug Administration (FDA) has approved the Takhzyro (lanadelumab-flyo) injection single-dose prefilled syringe (PFS) to prevent attacks of HAE in adult and pediatric patients 12 years of age and older. The PFS is ready to use and requires fewer preparation steps than the current Takhzyro vial injection, while also reducing supplies and waste.
“The announcement is an important innovation for Takhzyro, offering people living with HAE and their caregivers an enhanced treatment administration experience with proven sustained reduction of attacks. This product delivery enhancement is intended to improve the overall patient experience and reflects Takeda’s continued commitment to the HAE community; we look forward to introducing this new option to patients later this year”, says Cheryl Schwartz, Senior Vice President, Rare Disease Business Unit at Takeda Pharmaceutical Company Limited.
Takhzyro is supported by a robust clinical development program, which includes one of the largest prevention studies in HAE with the longest active treatment duration. Takhzyro is currently approved and available in more than 30 countries around the world.
(Source: Takeda)
